Nektar Therapeutics (NKTR) Change in Receivables (2010 - 2024)

Nektar Therapeutics' Change in Receivables history runs 15 years deep, the most recent figure standing at $2.2 million for Q4 2024.

• In Q4 2024, Change in Receivables rose 320.62% year-over-year to $2.2 million; the TTM figure through Sep 2025 stood at $2.2 million (up 1494.94% YoY), while the FY2024 annual figure was $3.0 million, up 163.76% from the prior year.
• Change in Receivables for Q4 2024 stood at $2.2 million, up from $850000.0 in the prior quarter.
• The five-year high for Change in Receivables was $7.7 million in Q1 2022, with the low at -$20.2 million in Q2 2022.
• The 5-year median for Change in Receivables is -$642000.0 (2021), against an average of -$1.6 million.
• The sharpest annual moves came in 2020 and 2022: Change in Receivables surged 1739.18% in 2020, then plunged 6992.63% in 2022.
• Nektar Therapeutics' Change in Receivables stood at -$8.0 million in 2020, then soared by 68.87% to -$2.5 million in 2021, then slumped by 121.86% to -$5.6 million in 2022, then surged by 82.0% to -$999000.0 in 2023, then soared by 320.62% to $2.2 million in 2024.
• Business Quant data shows NKTR's Change in Receivables at $2.2 million in Q4 2024, $850000.0 in Q3 2024, and -$2.4 million in Q2 2024.